Search
Promethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigational[A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.
Mixtures: COPHADYL-E COUGH LINCTUSCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeThrombin alfa
go.drugbank.com/drugs/DB11572ApprovedThe cell line used to manufacture Thrombin Alfa has been tested and shown to be free of known infectious agents. … The cell culture process used in the manufacture of Thrombin Alfa employs no additives of human or animal origin.
Levomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran]. … [L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeTromethamine
go.drugbank.com/drugs/DB03754ApprovedInvestigational(From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424) … It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used
Categories: Solutions Affecting the Electrolyte BalanceFostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigationalprevents the first step in the HIV-1 viral lifecycle. … [L14867] It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir
Sirolimus
go.drugbank.com/drugs/DB00877ApprovedInvestigational[A242372] The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with … [A242372] In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids.
Products: LIKMUN-EBaclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigationalAlthough originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.
Products: BACLENO® 10MG/5ML SOLUCIÓN DE PERFUSIÓNGlucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigationalIn 1983, the gene for carboxypeptidase G2, or glucarpidase, was derived from _Pseudomonas_ sp. strain RS-16 to be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities … [A7476,A7477] After the discovery of certain bacteria with the capacity to inactivate folate analogs such as methotrexate, carboxypeptidase G was identified and Carboxypeptidase G1 was first isolated
Sodium hydroxide
go.drugbank.com/drugs/DB11151ApprovedAccording to the the FDA, sodium hydroxide is considered a direct food recognized as safe, where it serves as a pH control agent and follows good manufacturing guidelines [L1967]. … The use of this compound has been shown to effectively reduce prion levels in an in vitro inactivation assay [A32334].
Mixtures: AMINOPLASMAL® 10% E, AMINOPLASMAL® 10% EClofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnIt was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. … Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy.